Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiati...
Gespeichert in:
Veröffentlicht in: | Oncotarget 2020-01, Vol.11 (4), p.399-408 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 408 |
---|---|
container_issue | 4 |
container_start_page | 399 |
container_title | Oncotarget |
container_volume | 11 |
creator | Noronha, Vanita Patil, Vijay Maruti Joshi, Amit Mahimkar, Manoj Patel, Usha Pandey, Manish Kumar Chandrasekharan, Arun Dsouza, Hollis Bhattacharjee, Atanu Mahajan, Abhishek Sabale, Nilesh Agarwal, Jai Prakash Ghosh-Laskar, Sarbani Budrukkar, Ashwini D'Cruz, Anil K Chaturvedi, Pankaj Pai, Prathamesh S Chaukar, Devendra Nair, Sudhir Thiagarajan, Shivakumar Banavali, Shripad Prabhash, Kumar |
description | Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiation could improve outcomes in these poor-risk tumors.
This was a subgroup analysis of a phase 3 randomized study. In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV)- radiation (66-70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66-70 Gy) {NCRT arm}. The data of HPV negative oropharyngeal cancer was extracted from the database of this study for the analysis. HPV testing was done with p16 immunohistochemistry (IHC) staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control, and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2 year OS with 95%CI was calculated. The hazard ratio was obtained using COX regression analysis.
We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (
= 0.000), locoregional control (
= 0.007) and overall survival (
= 0.002) but not for DFS (
= 0.072). The 2- year PFS was 31.5% (95%CI 21.5-42) in CRT arm versus 57.2% (95%CI 45.8-67.1) in NCRT arm (HR -0.54; 95%CI 0.36-0.79,
= 0.002). The 2-year LRC was 41.4% (95%CI 29.8-52.6) in the CRT arm versus in 60.4% (95%CI 48.7-70.2) in the NCRT arm (HR -0.61; 95%CI 0.4-0.94,
= 0.024). The addition of nimotuzumab also lead to an improvement in 2-year OS from 39.0% (95%CI 28.4-49.6) to 57.6% (95%CI 46.3-67.4) (HR-0.63, 95%CI 0.43-0.92,
= 0.018).
The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers. |
doi_str_mv | 10.18632/oncotarget.27443 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6996911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2356608921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3143-a5b59fe9f1862a9270b394cc4eb1212eb3945d5035da4aac84deda4c4983115d3</originalsourceid><addsrcrecordid>eNptUU1PwzAMjRCITWM_gAvqkUtH89U1FyQ0AUOagANwjdLU3YLaZCTtJPj1dB-MIeGL35PtZ1sPoXOcjHCWUnLlrHaN8nNoRmTMGD1CfSyYiAnn9PgA99AwhPekC87GGRGnqEdJkrKE0T6Sj6Z2TfvV1iqPtQnLSjXGxl4VpgPORivwoQ3RfyVjo-nzW2Rh3vEVRM675UL5TzsHVUVaWQ3-DJ2Uqgow3OUBer27fZlM49nT_cPkZhZrihmNFc-5KEGU3WtECTJOciqY1gxyTDCBNeMFTygvFFNKZ6yADmkmMooxL-gAXW91l21eQ6HBNl5VculN3V0knTLyb8WahZy7lUyFSAXGncDlTsC7jxZCI2sTNFSVsuDaIAnlaZpkgqxb8bZVexeCh3K_Bidy44389UZuvOlmLg7v20_8OEG_Ad6ikH8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356608921</pqid></control><display><type>article</type><title>Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free E- Journals</source><source>PubMed Central Open Access</source><creator>Noronha, Vanita ; Patil, Vijay Maruti ; Joshi, Amit ; Mahimkar, Manoj ; Patel, Usha ; Pandey, Manish Kumar ; Chandrasekharan, Arun ; Dsouza, Hollis ; Bhattacharjee, Atanu ; Mahajan, Abhishek ; Sabale, Nilesh ; Agarwal, Jai Prakash ; Ghosh-Laskar, Sarbani ; Budrukkar, Ashwini ; D'Cruz, Anil K ; Chaturvedi, Pankaj ; Pai, Prathamesh S ; Chaukar, Devendra ; Nair, Sudhir ; Thiagarajan, Shivakumar ; Banavali, Shripad ; Prabhash, Kumar</creator><creatorcontrib>Noronha, Vanita ; Patil, Vijay Maruti ; Joshi, Amit ; Mahimkar, Manoj ; Patel, Usha ; Pandey, Manish Kumar ; Chandrasekharan, Arun ; Dsouza, Hollis ; Bhattacharjee, Atanu ; Mahajan, Abhishek ; Sabale, Nilesh ; Agarwal, Jai Prakash ; Ghosh-Laskar, Sarbani ; Budrukkar, Ashwini ; D'Cruz, Anil K ; Chaturvedi, Pankaj ; Pai, Prathamesh S ; Chaukar, Devendra ; Nair, Sudhir ; Thiagarajan, Shivakumar ; Banavali, Shripad ; Prabhash, Kumar</creatorcontrib><description>Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiation could improve outcomes in these poor-risk tumors.
This was a subgroup analysis of a phase 3 randomized study. In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV)- radiation (66-70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66-70 Gy) {NCRT arm}. The data of HPV negative oropharyngeal cancer was extracted from the database of this study for the analysis. HPV testing was done with p16 immunohistochemistry (IHC) staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control, and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2 year OS with 95%CI was calculated. The hazard ratio was obtained using COX regression analysis.
We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (
= 0.000), locoregional control (
= 0.007) and overall survival (
= 0.002) but not for DFS (
= 0.072). The 2- year PFS was 31.5% (95%CI 21.5-42) in CRT arm versus 57.2% (95%CI 45.8-67.1) in NCRT arm (HR -0.54; 95%CI 0.36-0.79,
= 0.002). The 2-year LRC was 41.4% (95%CI 29.8-52.6) in the CRT arm versus in 60.4% (95%CI 48.7-70.2) in the NCRT arm (HR -0.61; 95%CI 0.4-0.94,
= 0.024). The addition of nimotuzumab also lead to an improvement in 2-year OS from 39.0% (95%CI 28.4-49.6) to 57.6% (95%CI 46.3-67.4) (HR-0.63, 95%CI 0.43-0.92,
= 0.018).
The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.27443</identifier><identifier>PMID: 32064043</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Research Paper</subject><ispartof>Oncotarget, 2020-01, Vol.11 (4), p.399-408</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3143-a5b59fe9f1862a9270b394cc4eb1212eb3945d5035da4aac84deda4c4983115d3</citedby><cites>FETCH-LOGICAL-c3143-a5b59fe9f1862a9270b394cc4eb1212eb3945d5035da4aac84deda4c4983115d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996911/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996911/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32064043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noronha, Vanita</creatorcontrib><creatorcontrib>Patil, Vijay Maruti</creatorcontrib><creatorcontrib>Joshi, Amit</creatorcontrib><creatorcontrib>Mahimkar, Manoj</creatorcontrib><creatorcontrib>Patel, Usha</creatorcontrib><creatorcontrib>Pandey, Manish Kumar</creatorcontrib><creatorcontrib>Chandrasekharan, Arun</creatorcontrib><creatorcontrib>Dsouza, Hollis</creatorcontrib><creatorcontrib>Bhattacharjee, Atanu</creatorcontrib><creatorcontrib>Mahajan, Abhishek</creatorcontrib><creatorcontrib>Sabale, Nilesh</creatorcontrib><creatorcontrib>Agarwal, Jai Prakash</creatorcontrib><creatorcontrib>Ghosh-Laskar, Sarbani</creatorcontrib><creatorcontrib>Budrukkar, Ashwini</creatorcontrib><creatorcontrib>D'Cruz, Anil K</creatorcontrib><creatorcontrib>Chaturvedi, Pankaj</creatorcontrib><creatorcontrib>Pai, Prathamesh S</creatorcontrib><creatorcontrib>Chaukar, Devendra</creatorcontrib><creatorcontrib>Nair, Sudhir</creatorcontrib><creatorcontrib>Thiagarajan, Shivakumar</creatorcontrib><creatorcontrib>Banavali, Shripad</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><title>Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiation could improve outcomes in these poor-risk tumors.
This was a subgroup analysis of a phase 3 randomized study. In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV)- radiation (66-70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66-70 Gy) {NCRT arm}. The data of HPV negative oropharyngeal cancer was extracted from the database of this study for the analysis. HPV testing was done with p16 immunohistochemistry (IHC) staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control, and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2 year OS with 95%CI was calculated. The hazard ratio was obtained using COX regression analysis.
We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (
= 0.000), locoregional control (
= 0.007) and overall survival (
= 0.002) but not for DFS (
= 0.072). The 2- year PFS was 31.5% (95%CI 21.5-42) in CRT arm versus 57.2% (95%CI 45.8-67.1) in NCRT arm (HR -0.54; 95%CI 0.36-0.79,
= 0.002). The 2-year LRC was 41.4% (95%CI 29.8-52.6) in the CRT arm versus in 60.4% (95%CI 48.7-70.2) in the NCRT arm (HR -0.61; 95%CI 0.4-0.94,
= 0.024). The addition of nimotuzumab also lead to an improvement in 2-year OS from 39.0% (95%CI 28.4-49.6) to 57.6% (95%CI 46.3-67.4) (HR-0.63, 95%CI 0.43-0.92,
= 0.018).
The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.</description><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptUU1PwzAMjRCITWM_gAvqkUtH89U1FyQ0AUOagANwjdLU3YLaZCTtJPj1dB-MIeGL35PtZ1sPoXOcjHCWUnLlrHaN8nNoRmTMGD1CfSyYiAnn9PgA99AwhPekC87GGRGnqEdJkrKE0T6Sj6Z2TfvV1iqPtQnLSjXGxl4VpgPORivwoQ3RfyVjo-nzW2Rh3vEVRM675UL5TzsHVUVaWQ3-DJ2Uqgow3OUBer27fZlM49nT_cPkZhZrihmNFc-5KEGU3WtECTJOciqY1gxyTDCBNeMFTygvFFNKZ6yADmkmMooxL-gAXW91l21eQ6HBNl5VculN3V0knTLyb8WahZy7lUyFSAXGncDlTsC7jxZCI2sTNFSVsuDaIAnlaZpkgqxb8bZVexeCh3K_Bidy44389UZuvOlmLg7v20_8OEG_Ad6ikH8</recordid><startdate>20200128</startdate><enddate>20200128</enddate><creator>Noronha, Vanita</creator><creator>Patil, Vijay Maruti</creator><creator>Joshi, Amit</creator><creator>Mahimkar, Manoj</creator><creator>Patel, Usha</creator><creator>Pandey, Manish Kumar</creator><creator>Chandrasekharan, Arun</creator><creator>Dsouza, Hollis</creator><creator>Bhattacharjee, Atanu</creator><creator>Mahajan, Abhishek</creator><creator>Sabale, Nilesh</creator><creator>Agarwal, Jai Prakash</creator><creator>Ghosh-Laskar, Sarbani</creator><creator>Budrukkar, Ashwini</creator><creator>D'Cruz, Anil K</creator><creator>Chaturvedi, Pankaj</creator><creator>Pai, Prathamesh S</creator><creator>Chaukar, Devendra</creator><creator>Nair, Sudhir</creator><creator>Thiagarajan, Shivakumar</creator><creator>Banavali, Shripad</creator><creator>Prabhash, Kumar</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200128</creationdate><title>Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer</title><author>Noronha, Vanita ; Patil, Vijay Maruti ; Joshi, Amit ; Mahimkar, Manoj ; Patel, Usha ; Pandey, Manish Kumar ; Chandrasekharan, Arun ; Dsouza, Hollis ; Bhattacharjee, Atanu ; Mahajan, Abhishek ; Sabale, Nilesh ; Agarwal, Jai Prakash ; Ghosh-Laskar, Sarbani ; Budrukkar, Ashwini ; D'Cruz, Anil K ; Chaturvedi, Pankaj ; Pai, Prathamesh S ; Chaukar, Devendra ; Nair, Sudhir ; Thiagarajan, Shivakumar ; Banavali, Shripad ; Prabhash, Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3143-a5b59fe9f1862a9270b394cc4eb1212eb3945d5035da4aac84deda4c4983115d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Noronha, Vanita</creatorcontrib><creatorcontrib>Patil, Vijay Maruti</creatorcontrib><creatorcontrib>Joshi, Amit</creatorcontrib><creatorcontrib>Mahimkar, Manoj</creatorcontrib><creatorcontrib>Patel, Usha</creatorcontrib><creatorcontrib>Pandey, Manish Kumar</creatorcontrib><creatorcontrib>Chandrasekharan, Arun</creatorcontrib><creatorcontrib>Dsouza, Hollis</creatorcontrib><creatorcontrib>Bhattacharjee, Atanu</creatorcontrib><creatorcontrib>Mahajan, Abhishek</creatorcontrib><creatorcontrib>Sabale, Nilesh</creatorcontrib><creatorcontrib>Agarwal, Jai Prakash</creatorcontrib><creatorcontrib>Ghosh-Laskar, Sarbani</creatorcontrib><creatorcontrib>Budrukkar, Ashwini</creatorcontrib><creatorcontrib>D'Cruz, Anil K</creatorcontrib><creatorcontrib>Chaturvedi, Pankaj</creatorcontrib><creatorcontrib>Pai, Prathamesh S</creatorcontrib><creatorcontrib>Chaukar, Devendra</creatorcontrib><creatorcontrib>Nair, Sudhir</creatorcontrib><creatorcontrib>Thiagarajan, Shivakumar</creatorcontrib><creatorcontrib>Banavali, Shripad</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noronha, Vanita</au><au>Patil, Vijay Maruti</au><au>Joshi, Amit</au><au>Mahimkar, Manoj</au><au>Patel, Usha</au><au>Pandey, Manish Kumar</au><au>Chandrasekharan, Arun</au><au>Dsouza, Hollis</au><au>Bhattacharjee, Atanu</au><au>Mahajan, Abhishek</au><au>Sabale, Nilesh</au><au>Agarwal, Jai Prakash</au><au>Ghosh-Laskar, Sarbani</au><au>Budrukkar, Ashwini</au><au>D'Cruz, Anil K</au><au>Chaturvedi, Pankaj</au><au>Pai, Prathamesh S</au><au>Chaukar, Devendra</au><au>Nair, Sudhir</au><au>Thiagarajan, Shivakumar</au><au>Banavali, Shripad</au><au>Prabhash, Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2020-01-28</date><risdate>2020</risdate><volume>11</volume><issue>4</issue><spage>399</spage><epage>408</epage><pages>399-408</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to determine whether the addition of nimotuzumab to cisplatin-radiation could improve outcomes in these poor-risk tumors.
This was a subgroup analysis of a phase 3 randomized study. In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV)- radiation (66-70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66-70 Gy) {NCRT arm}. The data of HPV negative oropharyngeal cancer was extracted from the database of this study for the analysis. HPV testing was done with p16 immunohistochemistry (IHC) staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control, and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2 year OS with 95%CI was calculated. The hazard ratio was obtained using COX regression analysis.
We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (
= 0.000), locoregional control (
= 0.007) and overall survival (
= 0.002) but not for DFS (
= 0.072). The 2- year PFS was 31.5% (95%CI 21.5-42) in CRT arm versus 57.2% (95%CI 45.8-67.1) in NCRT arm (HR -0.54; 95%CI 0.36-0.79,
= 0.002). The 2-year LRC was 41.4% (95%CI 29.8-52.6) in the CRT arm versus in 60.4% (95%CI 48.7-70.2) in the NCRT arm (HR -0.61; 95%CI 0.4-0.94,
= 0.024). The addition of nimotuzumab also lead to an improvement in 2-year OS from 39.0% (95%CI 28.4-49.6) to 57.6% (95%CI 46.3-67.4) (HR-0.63, 95%CI 0.43-0.92,
= 0.018).
The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>32064043</pmid><doi>10.18632/oncotarget.27443</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1949-2553 |
ispartof | Oncotarget, 2020-01, Vol.11 (4), p.399-408 |
issn | 1949-2553 1949-2553 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6996911 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free E- Journals; PubMed Central Open Access |
subjects | Research Paper |
title | Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T20%3A42%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nimotuzumab-cisplatin-radiation%20versus%20cisplatin-radiation%20in%20HPV%20negative%20oropharyngeal%20cancer&rft.jtitle=Oncotarget&rft.au=Noronha,%20Vanita&rft.date=2020-01-28&rft.volume=11&rft.issue=4&rft.spage=399&rft.epage=408&rft.pages=399-408&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.27443&rft_dat=%3Cproquest_pubme%3E2356608921%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2356608921&rft_id=info:pmid/32064043&rfr_iscdi=true |